National Research (NASDAQ:NRC) Price Target Raised to $27.00

National Research (NASDAQ:NRC) had its price target increased by Citizens Jmp from $26.00 to $27.00 in a research report report published on Wednesday,Benzinga reports. Citizens Jmp currently has a market outperform rating on the stock.

NRC has been the topic of several other research reports. Wall Street Zen lowered National Research from a “buy” rating to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings cut shares of National Research from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Friday, October 9th. Finally, Zacks Research raised shares of National Research to a “hold” rating in a report on Monday, October 5th. One analyst has rated the stock with a Buy rating and two have issued a Hold rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $27.00.

National Research Trading Up 1.4%

Shares of NASDAQ:NRC opened at $23.83 on Wednesday. National Research has a 52-week low of $11.73 and a 52-week high of $24.40. The stock has a market cap of $542.13 million, a price-to-earnings ratio of 85.11 and a beta of 0.25. The company has a quick ratio of 0.65, a current ratio of 0.65 and a debt-to-equity ratio of 13.13. The business has a 50-day moving average price of $21.22 and a 200-day moving average price of $19.20.

National Research (NASDAQ:NRC) last issued its quarterly earnings results on Tuesday, October 27th. The company reported $0.21 earnings per share for the quarter, topping the consensus estimate of $0.18 by $0.03. The company had revenue of $38.40 million for the quarter, compared to the consensus estimate of $35.80 million. National Research had a net margin of 4.48% and a return on equity of 171.97%. Equities analysts predict that National Research will post 0.98 EPS for the current year.

National Research Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, January 8th. Investors of record on Tuesday, December 29th will be paid a dividend of $0.16 per share. The ex-dividend date is Tuesday, December 29th. This represents a $0.64 annualized dividend and a yield of 2.7%. National Research’s payout ratio is presently 228.57%.

Institutional Investors Weigh In On National Research

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Bank of America Corp DE raised its stake in shares of National Research by 3.0% in the 1st quarter. Bank of America Corp DE now owns 112,468 shares of the company’s stock worth $1,910,000 after buying an additional 3,323 shares in the last quarter. Bank of New York Mellon Corp grew its stake in National Research by 4.0% during the 1st quarter. Bank of New York Mellon Corp now owns 250,707 shares of the company’s stock valued at $4,257,000 after acquiring an additional 9,730 shares in the last quarter. Hsbc Holdings PLC purchased a new position in shares of National Research during the 1st quarter valued at $180,000. Empowered Funds LLC acquired a new position in shares of National Research during the 1st quarter worth $226,000. Finally, Empirical Finance LLC acquired a new position in National Research during the second quarter worth $431,000. 47.26% of the stock is currently owned by institutional investors and hedge funds.

National Research Company Profile

National Research Corporation, formerly traded on the Nasdaq under the symbol NRC, provides research, analytics and performance-improvement services to the health care industry. Through its NRC Health business, the company helps hospitals, health systems and other care organizations understand and improve patient, consumer and employee experiences.

Its offerings have included patient and employee surveys, market research, reputation management, loyalty and engagement programs, benchmarking, and software tools that turn feedback and other data into operational insights.